Frank L Jr Jaksch, a director at $CDXC ($CDXC), sold 37,161 shares of the company on 12-13-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 13.2% of their...
Ozan Pamir, the Chief Financial Officer of $CDXC ($CDXC), bought 2,907 shares of the company on 11-22-2024. This trade was reported by Quiver Quantitative using data from a recent SEC filing. This increased...
U.S. stock markets started November, adding more steam to the ongoing rally. The primary reason was the anticipation of Donald Trump becoming the 47th president of the country. On Nov 5, Trump clinched...
ChromaDex Corp. (NASDAQ:CDXC) (“the Company”) a global bioscience company dedicated to healthy aging, announced that it will hold a conference call on Wednesday, May 10, 2023 at 4:30 p.m. ET to discuss...
ChromaDex Corp. (NASDAQ:CDXC) today announced fourth quarter and fiscal year 2022 financial results.
ChromaDex Corp. (NASDAQ:CDXC) (“the Company”) a global bioscience company dedicated to healthy aging, today announced that senior management will participate at the 35 th annual ROTH Capital Partners...
ChromaDex Corp. (NASDAQ:CDXC) (“the Company”), a global bioscience company dedicated to healthy aging, announced that it will hold a conference call on Wednesday, March 8, 2023 at 4:30 p.m. ET to...
ChromaDex Corp. (NASDAQ:CDXC), a global bioscience company dedicated to healthy aging, holds an exclusive license from Queen’s University Belfast for methods of making nicotinamide riboside (NR) and...
The following is issued on behalf of ChromaDex (NASDAQ: CDXC).
ChromaDex Corp. (NASDAQ:CDXC), a global bioscience company dedicated to healthy aging, announced promising findings from a first-of-its kind clinical study, as reported in the peer-reviewed journal Translational...